94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1561072
Research Progress on Ferroptosis in Myelodysplastic Syndromes
Provisionally accepted- 1 Shaoxing University, Shaoxing, China
- 2 Department of Hematology, Shaoxing People's Hospital, Chaoxing, China
Myelodysplastic syndromes (MDS) are a group of malignancies characterized by clonal proliferation of hematopoietic stem cells, ineffective hematopoiesis, peripheral cytopenias, and a high risk of transformation to acute myeloid leukemia. Current therapeutic strategies for MDS have limited efficacy. Thus, identifying new therapeutic targets and prognostic biomarkers is a critical future research direction. Ferroptosis, a new type of iron-dependent programmed cell death, has become a recent hotspot in the field of oncology research. Recent results have demonstrated that iron metabolism, lipid metabolism, and other pathways can be targeted to induce ferroptosis in MDS cells. In addition, ferroptosis-related genes are of significance in the prognosis and diagnosis of MDS. This article reviews the current research progress on ferroptosis in MDS, including its potential for targeting as a therapeutic intervention strategy.
Keywords: Myelodysplastic Syndromes, ferroptosis, Signal path, Ferroptosis-related genes, Ferroptosis inducing drugs
Received: 15 Jan 2025; Accepted: 12 Feb 2025.
Copyright: © 2025 Yang, Han, Wei, Jin and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Weiying Feng, Department of Hematology, Shaoxing People's Hospital, Chaoxing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.